Development of New Production Technologies for Humanized Antibodies

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$100,000.00
Award Year:
2004
Program:
STTR
Phase:
Phase I
Contract:
W911NF-04-C-0093
Award Id:
68418
Agency Tracking Number:
A045-006-0246
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
21823 30th Dr SE, Botthell, WA, 98021
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
145866096
Principal Investigator:
JohnLatham
Chief Scientific Officer, Founder
(425) 527-2703
latham@alderbio.com
Business Contact:
JohnLatham
Chief Scientific Officer, Founder
(425) 527-2703
latham@alderbio.com
Research Institute:
Keck Graduatate Institute
Brian Aufderheide
535 Watson Dr.
Claremont, CA, 91711
(909) 607-0398
Nonprofit college or university
Abstract
Humanized antibodies currently are produced through mammalian cell culture methods that require extensive resources, in particular, choosing the manufacturing cell line and the need for highly specialized cell growth facilities. These limitations have highlighted the need for new and more innovative ways for antibody production. Yeast heterologous protein expression systems have long been viewed as efficient and high yielding alternatives for mammalian cell line production. Yeast is able to deal with important folding and export issues that are unique to proteins found in higher eukaryotes, makes use of inexpensive media, has much greater routine commercialization, and enables significant reduction in cost and time for production. Antibody expression in this host provides an excellent solution for more efficient and expanded application of this class of therapeutics. In the case of antibodies, correct glycosylation was viewed a required feature. However, recent studies have questioned this requirement. Aglycosylated antibodies have been described to have comparable half-lives and retain function when the post-translational modification is eliminated. It is in this light that our proposal focuses on the use of Pichia pastoris as a new host for full-length antibody expression building on the extensive success this system has had for the production of therapeutic proteins.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government